During the year, the Group recorded revenue of approximately
The Board of Directors has recommended a final dividend payment of HK3 cents per share (2022: HK6 cents). Together with the interim dividend of HK2 cents already paid, the total dividend for the year amounted to HK5 cents (2022: HK12 cents).
Sales: Strong and effective sales system continued to drive sales and revenue of innovative products
On the strong foundation its generic drug business provides, the Company is transforming at full steam powered by innovation, with innovative products business driving revenue growth and contributing an increasing share to its revenue every year. Revenue from innovative products amounted to
During the year, the sales of oncology medicines amounted to approximately
R&D: Vigorously conducted innovative product R&D and actively applied for patents
The Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver diseases, respiratory system and surgery/analgesia. As at the end of the reporting period, the Group had 145 products under development, including 60 oncology products, 9 liver disease products, 31 respiratory system products, and 15 surgery/analgesia products, of which 67 were Category I innovative products.
The Group also attaches tremendous importance to the protection of intellectual property rights and encourages its member enterprises to file patent applications in order to enhance the Group's core competitiveness. During the reporting period, the Group filed 841 new patent applications and received 264 patent invention approvals. As at the end of the reporting period, the Group had accumulated 4,311 effective patents and patent applications and obtained 1,595 patent invention approvals.
Prospects: Enhanced the efficiency of R&D in the four main therapeutic areas and actively promoted the dual-pronged development strategy
With the COVID-19 pandemic gradually subsiding, the economic and social order has returned to normal, and the pharmaceutical industry is expected to recover. The Group has been closely monitoring the development of the country, society and industry, and has made timely adjustments to its development strategies, focused on the operation of core assets to realize rapid business development and steady improvement in results.
Sino Biopharm is committed to "be a leading global pharmaceutical company through delivering innovative therapies for patients". The Group has stepped up its R&D investment in medicines and built strong internal R&D capabilities. At the same time, it has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises. At present, the Group has entered the harvest period of its innovative development. In the next three years, more than 10 innovative products are expected to be launched to market, and another 30 or more innovative products under R&D have the potential to be launched by 2030, which will further promote the high-quality development, strengthen the Group's dominance in the four aforementioned therapeutic areas and provide strong impetus for its future sustainable growth. Meanwhile, the Group will adhere to its dual-pronged approach in the implementation of its globalization strategy, so as to become an important platform of global innovation. Through this approach, the Group will introduce global pharmaceutical innovations to
Looking ahead, the Group will further focus on its core business and innovation, and continue to improve R&D efficiency and quality in the four major therapeutic areas. It will also actively accelerate the deployment for globalization of its business and is expected to achieve faster growth in 2024.
About
For more information, please visit: www.sinobiopharm.com
Copyright 2024 ACN Newswire . All rights reserved.
© Japan Corporate News, source